AstraZeneca and Daiichi Sankyo Report Disappointing Phase 3 Overall Survival Data for Dato-DXd in NSCLC

Intelligent Finance APP learned that AstraZeneca (AZN.US) and Daiichi Sankyo stated that the Phase 3 study of their antibody-drug conjugate (ADC) datopotamab deruxtecan (also known as Dato-DXd) showed it did not significantly extend patient life compared to the chemotherapy drug docetaxel.

According to a statement, while the overall survival results of the study favored Dato-DXd, they did not reach statistical significance.

However, the data does show that the overall survival for non-squamous non-small cell lung cancer (NSCLC) patients taking Dato-DXd was 14.6 months, which is an improvement of 2.3 months compared to the 12.3 months overall survival for patients treated with docetaxel.

No overall survival improvement was observed in squamous NSCLC patients.

Affected by this news, AstraZeneca's share price closed down 2.6% on Monday.